Top Ten most popular articles on this week

pharmafile | November 29, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, Jeremy Corbyn, NHS, Opiod, US, opiod crisis 

The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which opening up the NHS to US drug firms were brought up. A report was also released this week showing that the majority of British people are concerned about the fate of the NHS due to the US trade deal; however this survey was conducted before this week’s revelations.

In the US, Federal Prosecutors from the US Attorney’s Office in the Eastern District of New York have subpoenaed five opioid manufactures. This adds to the growing legal fight against pharmaceutical companies who have been complicit in the opioid crisis which has ravaged the America.

10. Drugmakers cut prices by 61% to get on Chinese reimbursement list

AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s national reimbursement scheme list. The average price cut is about 61%.

9. FDA fast-tracks psilocybin treatment for major depressive disorder

The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the treatment of major depressive disorder (MDD), with the view of accelerating trials testing its efficacy.

8. AstraZeneca and Novoheart team up to develop human ‘heart-in-a-jar’

AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind.

7. US prosecutors open criminal probe of six drugs companies in opioid investigation

Federal Prosecutors from the US Attorney’s Office in the Eastern District of New York have subpoenaed five opioid manufactures.

6. FDA approves GBT’s Oxbryta to treat sickle cell disease

The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which is used to treat sickle cell disease.

5. Majority of British people worried about the fate of the NHS in post-Brexit US trade deal, survey reveals

In a newly released survey on “Over-The-Counter (OTC) and Pharma 2019”, by the business data platform Statista, 55% of people surveyed were concerned about the potential post-Brexit trade deal with the US and its impact on the NHS.

4. Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to be made available via the Cancer Drugs Fund.

3. Novartis acquires The Medicines Company in a deal worth $9.7 billion

Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously approved by the boards of both companies and Novartis will pay $85 per share.

2. Europe approves first subcutaneous version of biosimilar infliximab

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation of the therapy, it has emerged.

1. Corbyn reveals documents showing US-UK meetings on deregulating NHS drug pricing

Labour Leader Jeremy Corbyn has showed off documents that detail secret trade meetings between the US and UK Governments, where US corporations were seeking to force up prices for NHS drugs.

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence …


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Latest content